Prothena earns $40M milestone from Novo Nordisk for ATTR cardiomyopathy drug advance

PROTHENA CORP PUBLIC LTD CO

$40 million milestone payment from Novo Nordisk triggered by continued Phase 2 study of NNC6019 for ATTR cardiomyopathy.
Total potential milestone payments up to $1.2 billion; $100 million earned to date including this payment.
Novo Nordisk acquired full worldwide rights to ATTR amyloidosis pipeline from Prothena in July 2021.
Phase 2 study addresses high unmet need in moderate to advanced ATTR amyloidosis with risk of early mortality.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.